FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau/File Photo
(Reuters) - Bristol-Myers Squibb Co expressed disappointment on Thursday with the opposition of its top shareholder to a $74 billion takeover of Celgene Corp, and said it would press on with what would be the largest pharmaceutical acquisition of all time.
Shares of the U.S. drugmaker were up 2 percent, while those of its smaller rival fell 8 percent before the opening bell, a day after asset manager Wellington Management said on Wednesday it did not support the deal to buy Celgene.
In a letter to employees, Bristol-Myers reiterated that the Celgene deal is the best path forward for the company and that it continued to believe strongly in the merits of the deal.
Reporting by Ankur Banerjee in Bengaluru; Editing by Saumyadeb Chakrabarty
Our Standards:The Thomson Reuters Trust Principles.Related reporting
More Business News →
High Court Blocks Oigara Bank Fraud Probe as Stanbic CEO Escapes Questioning
15 Proven Ways to Make Money Online in Kenya; No Scams!
High Court Halts Equity Bank's Takeover Bid on Swafi Foods in Landmark Ruling
